Project Details
Description
這個研究結果會讓我們了解Gal-1在HBV引發肝癌幹細胞特性和Sorafenib抗藥機制的重要性，利用標靶Gal-1來同時治療HBV引發的肝纖維化和降低肝癌幹細胞特性，在未來可能成為一個新的輔助療法來降低Sorafenib抗藥性以達到更好的療效。
| Status | Finished |
|---|---|
| Effective start/end date | 8/1/20 → 7/1/21 |
The Role of Galectin-1 in Liver Fibrosis-Promoted Stem-Like Cell Properties and Sorafenib-Refractoriness of Hbv-Related Hepatocellular Carcinoma( III )
- Wu, Ming-Heng (PI)
Project: A - Government Institution › b - National Science and Technology Council